These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 20831533)

  • 1. Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia.
    Sugioka N; Takai M; Yoshida K; Yasuda K; Fukushima K; Kokuhu T; Okamoto M; Yoshimura N; Takada K
    J Clin Pharm Ther; 2010 Jun; 35(3):323-32. PubMed ID: 20831533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure.
    Sugioka N; Fujimoto K; Tanaka Y; Fukushima K; Ito Y; Kokuhu T; Okamoto M; Yoshimura N; Takada K
    Drug Metab Lett; 2009 Aug; 3(3):152-61. PubMed ID: 19702545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
    Sugioka N; Kokuhu T; Okamoto M; Yoshimura N; Ito Y; Shibata N; Takada K
    J Pharm Pharmacol; 2006 Sep; 58(9):1193-200. PubMed ID: 16945177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperuricaemia in cyclosporin-treated patients: GFR-related effect.
    Zürcher RM; Bock HA; Thiel G
    Nephrol Dial Transplant; 1996 Jan; 11(1):153-8. PubMed ID: 8649625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
    Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
    Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients.
    Tarek BO; Nadia BF; Anis K; Saloua L; Abderrahmane A; Lamia T; Amel L; Mohamed L
    Transplant Proc; 2010 Nov; 42(9):3735-8. PubMed ID: 21094848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
    Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
    Taylor PJ; Kubler PA; Lynch SV; Allen J; Butler M; Pillans PI
    Ann Pharmacother; 2004 Feb; 38(2):205-8. PubMed ID: 14742751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients.
    Brunner LJ; Munar MY; Vallian J; Wolfson M; Stennett DJ; Meyer MM; Bennett WM
    Pharmacotherapy; 1998; 18(1):23-9. PubMed ID: 9469677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study.
    Busnach G; Stragliotto E; Minetti E; Perego A; Brando B; Broggi ML; Civati G
    J Nephrol; 1998; 11(2):87-93. PubMed ID: 9589380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem.
    Aros CA; Ardiles LG; Schneider HO; Flores CA; Alruiz PA; Jerez VR; Mezzano SA
    Transplant Proc; 2005 Oct; 37(8):3364-6. PubMed ID: 16298597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of orange and tangerine juice on cyclosporine levels in renal transplant recipients.
    Sorkhi H; Oliaei F; Moghadamnia AA; Pouramin M; Firoozjahi AR
    Transplant Proc; 2007 May; 39(4):1228-30. PubMed ID: 17524940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
    Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
    Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.